BCEL Key Statistics, Chart & Performance
The current stock price of BCEL is 0.15 USD. In the past month the price decreased by -51.61%. In the past year, price decreased by -87.8%.
BCEL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCEL. When comparing the yearly performance of all stocks, BCEL is a bad performer in the overall market: 97.03% of all stocks are doing better.
BCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCEL. BCEL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BCEL Financial Highlights
Over the last trailing twelve months BCEL reported a non-GAAP Earnings per Share(EPS) of -1.95. The EPS increased by 29.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -371.75% | ||
| ROE | -905.28% | ||
| Debt/Equity | 0 |
BCEL Forecast & Estimates
10 analysts have analysed BCEL and the average price target is 5.61 USD. This implies a price increase of 3640% is expected in the next year compared to the current price of 0.15.
BCEL Ownership
BCEL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCEL
Company Profile
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Company Info
ATRECA INC - A
835 Industrial Road,, 75 Shoreway Road, Suite C
San Carlos CALIFORNIA 94063 US
CEO: John A. Orwin
Employees: 90
Phone: 16505952595
ATRECA INC - A / BCEL FAQ
What does BCEL do?
Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. The company is headquartered in San Carlos, California and currently employs 90 full-time employees. The company went IPO on 2019-06-20. The firm is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The company is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
What is the stock price of ATRECA INC - A today?
The current stock price of BCEL is 0.15 USD. The price decreased by -11.76% in the last trading session.
What is the dividend status of ATRECA INC - A?
BCEL does not pay a dividend.
How is the ChartMill rating for ATRECA INC - A?
BCEL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BCEL stock to perform?
10 analysts have analysed BCEL and the average price target is 5.61 USD. This implies a price increase of 3640% is expected in the next year compared to the current price of 0.15.
What is ATRECA INC - A worth?
ATRECA INC - A (BCEL) has a market capitalization of 5.94M USD. This makes BCEL a Nano Cap stock.